Generate Biomedicines

Asthma-focused AI biotech Generate Biomedicines files for a $100 million US IPO IPO Overview Generate Biomedicines, a Phase 3 biotech using an AI drug discovery platform to develop severe asthma therapies, filed on Wednesday with the SEC to raise up... Read more